Skip to Content

JavaScript has been disabled within your browser, the content or the functionality of this web page can be limited or unavailable.

There is no panel matching the key "Alert---Site-Wide"

Clinical Trials Search Results

Search for

in

Accepting Participants (5)
Complete (1)

Showing 1-5 of 5

Sorted By:

A-Z
Z-A

Previous Next

ALLO-501A-202: A Randomized, Open-Label Study Evaluating the Efficacy and Safety of Cemacabtagene Ansegedleucel in Participants with Minimal Residual Disease after Response to First Line Therapy for Large B-Cell Lymphoma (ALPHA3)
ALLO-501A-202 Randomized, Open-Label Study Evaluating Efficacy and Safety Cemacabtagene Ansegedleucel for Large B-Cell Lymphoma (ALPHA3)
BGB-21447-101: A Phase 1/1b Open-Label Dose-Escalation and Dose-Optimization Study of Bcl-2 Inhibitor BGB-21447 in Patients With Mature B-Cell Malignancies {enrollment closed 12/22/25}
A Phase 1/1b Open-Label Dose-Escalation and Dose-Optimization Study of Bcl-2 Inhibitor BGB-21447 in Patients With Mature B-Cell Malignancies
JCAR017-EAP-001: Expanded Access Protocol (EAP) for Subjects Receiving Lisocabtagene Maraleucel that is Nonconforming for Commercial Release
This is an expanded access protocol that will be conducted at sites qualified and approved to treat subjects with lisocabtagene maraleucel.
KT-US-471-0140: Expanded Access Study for the Treatment of Patients with Commercially Out-of-Specification Axicabtagene Ciloleucel
Provide access to axicabtagene ciloleucel for patients with a disease approved for treatment with axicabtagene ciloleucel, out of specification for commercial release.
KT-US-472-0141: Expanded Access Study for the Treatment of Patients with Commercially Out-of-Specification Brexucabtagene Autoleucel
Provide access to brexucabtagene autoleucel for patients with a disease approved for treatment, that is otherwise out of specification for commercial release.

Previous Next